The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

Coco Gauff advanced to the fourth round of the Cincinnati Open after her opponent withdrew due to illness. Gauff will have ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in ...

By HOWARD FENDRICH AP Tennis Writer Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her first Grand Slam competition in two years.

Jill M. Kramer, DDS, PhD, associate professor in the Department of Oral Biology at the University at Buffalo School of Dental ...